Notebook

November was a rollercoaster month at the National Academy of Sciences (NAS). First, the United States Supreme Court declined to hear NASA's appeal of a lower court ruling subjecting the academy and its committees to the Federal Advisory Committees Act (FACA) of 1972. Animal rights groups argued that under FACA there should have been more public representation on a committee set up to revise the NIH Guide for the Care and Use of Laboratory Animals (R. Finn, The Scientist, July 22, 1996, page 1)

| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

November was a rollercoaster month at the National Academy of Sciences (NAS). First, the United States Supreme Court declined to hear NASA's appeal of a lower court ruling subjecting the academy and its committees to the Federal Advisory Committees Act (FACA) of 1972. Animal rights groups argued that under FACA there should have been more public representation on a committee set up to revise the NIH Guide for the Care and Use of Laboratory Animals (R. Finn, The Scientist, July 22, 1996, page 1), and that the committee's deliberations should have been open. But Congress immediately took steps to counter NASA's judicial defeat. By mid-month both the House and the Senate had passed identical amendments to FACA requiring NAS committee meetings to be open to the public only when the committee is gathering data or hearing testimony. Meetings in which committees deliberate their recommendations may continue to be closed. At ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies